Chemo Brain — Cancer-Related Cognitive Changes

Cancer-related cognitive impairment is a multifactorial neurocognitive condition marked by subtle declines in executive functioning, processing speed, attention span, and working memory. Although traditionally attributed solely to cytotoxic drugs, current evidence indicates that chemo brain can stem from a broader interplay of cancer therapies, including hormone therapy, immunotherapy, and targeted treatments, as well as neuroinflammation triggered by the malignancy itself.

Biologically, neurotoxic chemotherapy agents and systemic inflammatory cytokines cross or disrupt the blood-brain barrier, altering microglial function, suppressing neurogenesis in the hippocampus, and causing microvascular injury. Other contributing physiological factors include anaesthesia exposure, persistent fatigue, sleep disruption, emotional distress, and treatment-induced premature menopause or hormonal shifts.

Experiencing cognitive changes can be unsettling and interfere with your confidence, work performance, and personal life. Acknowledging chemo brain validates that these challenges are medical rather than personal failings. Discussing these symptoms with your oncology team enables early assessment and access to supportive interventions, such as cognitive rehabilitation, occupational therapy, and practical coping tools. Proactive management helps reduce frustration, minimises stress, and supports a smoother return to daily routines.

There is no single blood biomarker or imaging scan that diagnoses chemo brain. Clinical neuropsychologists evaluate cognitive function using formal neuropsychological batteries that measure verbal memory, processing speed, and executive skills. Blood tests—such as thyroid function panels, complete blood counts (to detect anaemia), and vitamin B12 levels—are routinely performed to rule out other treatable, reversible causes of cognitive sluggishness.

Chemo brain is reported across numerous tumour types. It is most extensively documented in people treated for breast cancer, largely due to high survival rates, comprehensive survivorship studies, and the additive cognitive effects of long-term endocrine therapy. It is also frequently reported by patients undergoing treatment for haematological cancers, colorectal cancer, prostate cancer, and primary brain tumours.

Identifying cognitive changes influences treatment planning and supportive care. While rarely prompting a reduction in life-saving curative therapy, severe symptoms may lead clinicians to adjust supportive medications, address sleep disruption, or manage treatment-related anaemia and fatigue. Management focuses on cognitive rehabilitation, structured aerobic exercise (which stimulates neuroplasticity), cognitive behavioural therapy (CBT), and sometimes off-label medications like methylphenidate or modafinil for severe cases.